D NJ ruling in favor of AstraZeneca in Seroquel case

U.S. District Judge Joel Pisano in Trenton, New Jersey ruled in favor of AstraZeneca in the Seroquel matter on July 1, and AstraZeneca can ask Judge Pisano to block Teva and Sandoz from getting U.S. regulatory approval to sell copies of Seroquel until the patent expires in 2011.

Bloomberg noted: AstraZeneca is trying to broaden Seroquel's use to keep revenue rising as sales of its No. 1 product, the Nexium ulcer treatment, fall. (...) AstraZeneca said in January that it holds a 32 percent share of U.S. antipsychotic drug prescriptions, boosted by the extended release version introduced in August. Seroquel sales, which rose 18 percent in 2007 from the year before, are likely to increase as the therapy wins approval for new indications such as bipolar disorder. Citigroup's Wilson estimates that the treatment may bring in $4.4 billion this year.

See also:

http://ipbiz.blogspot.com/2007/05/newark-star-ledger-on-ksr-impact-on.html

http://ipbiz.blogspot.com/2005/10/ranbaxy-challenges-astrazenecas-nexium.html